Clearmind Medicine’s CMND-100 Meets Primary Endpoint in FDA-Approved Phase I/IIa Clinical Trial for Alcohol Use Disorder

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 7/6/2026

1. MU
2. SPY
3. APTX:CN
4. IQMX
5. EROC
6. MSTR
7. RIVN
8. TSLA
9. MSFT
10. SEER

Go back to Clearmind Medicine’s CMND-100 Meets Primary Endpoint in FDA-Approved Phase I/IIa Clinical Trial for Alcohol Use Disorder
(NASDAQ: CMND) Delayed: 2.34 -0.02 (0.85%)
Previous Close $2.36    52 Week High $ 
Open $2.28    52 Week Low $ 
Day High $2.35    P/E N/A 
Day Low $2.22    EPS $ 
Volume 33,383